Clinically Relevant Drug Interactions for Malaria
Interactions between different substances and molecules in the human body have occurred for as long as humans have existed. Usually this is not something that we notice. However, with the increased use of pharmaceutical drugs, drug-drug interactions have become increasingly more important since it has the potential to make drugs ineffective or toxic. Less effective drugs can lead to a delayed, decreased, or absent pharmaceutical effect and therefore not yield the promised treatment for the disease and/or symptom. Reduced effect can also result in increased risk of resistance development in anti-infective treatments. Drug toxicity can result in adverse events (i.e., side effects) and in some cases even death.
Malaria is a life-threatening disease that may result in death if left untreated, and a degree of drug-drug interactions might therefore be a necessary risk. Thus, it is important to consider drug-drug interactions, given the many drugs that are potentially...
- Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67(9):2213–21.PubMedPubMedCentralCrossRefGoogle Scholar
- Centers for Disease Control and Prevention. Treatment for TB Disease | Treatment | TB | [Internet]. 2018 [cited 2018 Sep 6]. Available from: https://www.cdc.gov/tb/topic/treatment/tbdisease.htm
- Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr. 2003;33(5):551–6.PubMedCrossRefGoogle Scholar
- European Medicines Agency. Assessment report Eurartesim. 2011.Google Scholar
- Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014;58(12):7340–6.PubMedPubMedCentralCrossRefGoogle Scholar
- Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, et al. Parasite clearance and artemether pharmacokinetics parameters over the course of artemether-lumefantrine treatment for malaria in human immunodeficiency virus (HIV)-infected and HIV-uninfected ugandan children. Open Forum Infect Dis. 2016;3(4):ofw217.PubMedPubMedCentralCrossRefGoogle Scholar
- Kajubi R, Huang L, Jagannathan P, Chamankhah N, Were M, Ruel T, et al. Antiretroviral therapy with efavirenz accentuates pregnancy-associated reduction of dihydroartemisinin-piperaquine exposure during malaria chemoprevention. Clin Pharmacol Ther. 2017;102(3):520–8.PubMedPubMedCentralCrossRefGoogle Scholar
- Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. 2016. Clinical Infectious Diseases, https://academic.oup.com/cid/article/63/7/e147/2196792?searchresult=1.
- Pinilla YT, Lopes CPS, Sampaio SV, Andrade FS, Melo GC, Orfanó AS, et al. Promising approach to reducing Malaria transmission by ivermectin: sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. Milon G, editor. PLoS Negl Trop Dis. 2018;12(2):e0006221.PubMedPubMedCentralCrossRefGoogle Scholar
- Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong’o BO, Chen T, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis Elsevier. 2018;18(6):615–26.CrossRefGoogle Scholar
- Tchaparian E, Sambol NC, Arinaitwe E, McCormack SA, Bigira V, Wanzira H, et al. Population pharmacokinetics and pharmacodynamics of lumefantrine in young Ugandan children treated with artemether-lumefantrine for uncomplicated Malaria. J Infect Dis. 2016;214(8):1243–51. UNAIDS. UNAIDS data 2018. 2018.PubMedPubMedCentralCrossRefGoogle Scholar
- UNAIDS | UNAIDS data 2018 | [Internet]. 2018 [cited 2018 Aug 22]. Available from: http://www.unaids.org/en/resources/documents/2018/unaids-data-2018.
- WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015.Google Scholar
- World Health Organization. Treatment of Tuberculosis. 2010.Google Scholar
- World Health Organization. TUBERCULOSIS REPORT 2017 GLOBAL. 2017.Google Scholar
- World Health Organization. World malaria report 2017. World Health Organization; 2018.Google Scholar
- Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42(1):52–60.PubMedGoogle Scholar
- Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005;33(11):1729–39.PubMedCrossRefGoogle Scholar